Compare TFIN & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TFIN | CMPS |
|---|---|---|
| Founded | 1981 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2014 | 2020 |
| Metric | TFIN | CMPS |
|---|---|---|
| Price | $62.45 | $15.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $66.20 | $25.38 |
| AVG Volume (30 Days) | 162.1K | ★ 2.3M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.22 | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.27 | N/A |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | $94.03 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $46.43 | $4.83 |
| 52 Week High | $83.52 | $15.87 |
| Indicator | TFIN | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 21.78 | 60.08 |
| Support Level | $60.93 | $12.95 |
| Resistance Level | $65.37 | $15.87 |
| Average True Range (ATR) | 1.97 | 0.82 |
| MACD | -0.53 | 0.06 |
| Stochastic Oscillator | 7.37 | 76.47 |
Triumph Financial Inc is a financial holding company based in the United States. Along with its subsidiaries, the company operates in four reportable segments: Banking, Factoring, Payments, and Intelligence. The Banking segment, which generates maximum revenue, includes the operations of TBK Bank, offering traditional banking services. The Factoring segment provides working capital solutions to the trucking industry through the purchase of invoices generated by carriers at a discount. The Payments segment provides payment, audit, and other banking services for the over-the-road trucking industry, and the Intelligence segment operates to turn the over-the-road trucking data collected through the services offered into actionable insights for its customers.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.